At the recent BioStock Summit in Lund, Aixial’s experts, Ashley Hunter, Senior Director of Clinical Operations and Head of Strategic Development & Delivery, and Anna Yanaeva, Senior Director for Business Development, led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development”.

Clear communication is essential to drug development. At Aixial Group, our experienced medical writers know how to turn complex scientific data into clear, accurate documents. From regulatory protocols to scientific publications, they ensure clarity and compliance at every stage.

Digitalisation — Clinical trials are essential research studies evaluating medical intervention safety and efficacy, with varying designs and phases aimed at understanding treatment effects and patient experiences…

Pancreatic cancer is the 12th most common cancer in the world and remains one of the deadliest, with a five-year survival rate of only 13%, despite recent progress.

Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer. 

Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.